A new HHS report on questionable medical billing is part of a broader—yet at times inconsistent—effort to challenge pharmaceutical influence, improve nutrition, lower healthcare costs, and shift federal policy toward prevention.
Listen to the audio version of this article:
THE TOPLINE
- A new HHS report alleges that hospitals used questionable diagnostic codes to obtain insurance reimbursement for expensive medical interventions, exposing how financial incentives can distort patient care.
- Over the last two years, HHS has also advanced food-dye reform, infant-formula testing, nutrition education, drug-price negotiations, price transparency, and prior-authorization reform.
- These actions represent meaningful progress, but HHS must apply its skepticism consistently—including when FDA policies threaten individualized, natural, and non-patentable treatments.
A new report commissioned by the Department of Health and Human Services (DHHS) examines how financial incentives, institutional ideology, and questionable billing practices may have driven children toward expensive, long-term medical interventions.
One underlying issue—pediatric gender medicine—is highly charged politically. But the systemic problem identified by HHS is much broader: hospitals and pharmaceutical companies can profit when otherwise healthy people become lifelong medical patients.
Among its findings, the report identified nearly $11 million in claims from 2015 through 2025 for puberty blockers given to patients between 13 and 17 under a diagnosis of “precocious puberty.” Yet that diagnosis traditionally applies when puberty begins before age eight in girls or nine in boys; treatment is generally discontinued around ages ten or eleven.
HHS acknowledges that its claims analysis provides “directional signals” requiring verification against medical records. But it raises a serious possibility: providers may have used a physical endocrine diagnosis to obtain insurance coverage for drugs prescribed for a different condition.
If confirmed, this is a stark example of how reimbursement can corrupt medical decision-making. But it is not the only area where HHS has begun confronting the forces that keep Americans dependent on an expensive, intervention-heavy healthcare system.
Shifting the Focus to Food and Prevention
HHS and USDA released new Dietary Guidelines for Americans in January 2026 emphasizing whole foods, protein, healthy fats, fruits, vegetables, and home-prepared meals while discouraging heavily processed foods and artificial additives.
HHS and FDA have also announced an initiative to phase out six widely used petroleum-based synthetic dyes through industry cooperation by the end of 2027. Because much of that initiative remains voluntary, its ultimate impact will depend on whether manufacturers fulfill their commitments. Nevertheless, major companies are already reformulating products, and FDA has approved several non-petroleum alternatives. The agency is also pressing manufacturers to remove Red No. 3 before its 2027 food deadline, although the decision to revoke that dye’s authorization was made before Secretary Kennedy took office.
Another meaningful step is Operation Stork Speed, FDA’s first comprehensive review of infant-formula nutrient requirements since 1998. In April 2026, FDA released results from testing more than 300 formula samples for heavy metals, pesticides, PFAS, phthalates, and other contaminants. Most showed undetectable or very low levels, but FDA says it is conducting follow-up testing and developing contaminant action levels.
HHS has also secured voluntary commitments from over 70 medical schools in 31 states to provide at least 40 hours of nutrition education—or a competency-based equivalent—beginning in fall 2026. The department developed 71 suggested nutrition competencies and dedicated $5 million to an NIH nutrition-education challenge. These are voluntary rather than mandatory, but they address a glaring weakness in conventional medical training.
Challenging Healthcare Costs and Bureaucracy
The administration has reached drug-pricing agreements with 26 manufacturers, which it says represent 89 percent of the branded-drug market. The agreements provide most-favored-nation pricing in state Medicaid programs and discounted direct-purchase options for selected medicines. This does not mean every American now pays the world’s lowest price for every drug, but it represents a real challenge to pharmaceutical pricing power.
CMS has also strengthened hospital price-transparency requirements, including disclosure of cash prices, insurer-negotiated rates, and consumer-friendly pricing for at least 300 shoppable services. During his first term, President Trump established landmark rules requiring hospitals and insurers to disclose their negotiated prices and give patients cost-estimation tools. Since then, compliance and usability problems have persisted. The current administration has now imposed additional hospital requirements based on actual payment data and proposed further reforms to make insurer information easier to locate, standardize and compare.
Meanwhile, participating insurers have eliminated approximately 11 percent of prior-authorization requirements—about 6.5 million fewer authorizations—and new federal deadlines require faster decisions for Medicare Advantage, Medicaid, CHIP, and federal Marketplace plans. Prior authorization remains widespread, but this is tangible progress.
The Test Is Consistency
Taken together, these initiatives suggest a welcome shift: toward prevention, better nutrition, greater transparency, lower drug prices, and closer scrutiny of medical institutions that profit from chronic intervention.
But HHS cannot challenge the medical-industrial complex selectively. The same department includes an FDA that continues to threaten access to compounded medicines, natural desiccated thyroid, peptides, homeopathy, and other individualized or non-patentable treatments. So far, our legal initiatives aiming to open up free speech about natural products and to protect homeopathy have, unfortunately, been stymied by HHS or the FDA, demonstrating how deep the institutional bias towards Big Pharma runs.
The new direction is encouraging. The real test will be whether HHS consistently chooses patient health, informed choice, and medical freedom over institutional power—wherever that power is found.
Please share this article widely in your networks.
